Vernakalant for cardioversion of recent-onset atrial fibrillation: a systematic review and meta-analysis.

ABSTRACT:

Aims

To evaluate the efficacy and safety of vernakalant for the cardioversion of atrial fibrillation (AF).

Methods and results

We reviewed the literature for randomized trials that compared vernakalant to another drug or placebo in patients with AF of onset ≤7 days. We used a random-effects model to combine quantitative data and rated the quality of evidence using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation). From 441 total citations in MEDLINE, EMBASE, and CENTRAL (December 2018), we identified nine trials evaluating 1358 participants. Six trials compared vernakalant to placebo, two trials compared vernakalant to ibutilide, and one trial compared vernakalant to amiodarone. We found significant methodological bias in four trials. For conversio

SUBMITTER: McIntyre WF 

PROVIDER: S-EPMC6680366 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature